Undisclosed LNP-mRNA-based in vivo CAR-T / Moderna - LARVOL DELTA

Targeted Delivery of mRNA for In Vivo CAR-T Therapy Induces Deep B-Cell Depletion Across Blood and Lymphoid Tissues in Humanized Mouse and Nonhuman Primate (NHP) Models and in Ex Vivo SLE Patient Samples (ACR Convergence 2026) - "These studies demonstrate preclinical proof-of-concept for a targeted LNP-mRNA-based in vivo CAR-T therapy capable of generating functional CAR-expressing immune effector cells and inducing deep B-cell depletion across peripheral blood and multiple lymphoid tissue compartments. The ability to achieve substantial activity within lymphoid tissues, including lymph nodes, without lymphodepleting conditioning supports the potential of this approach as a re-dosable, off-the-shelf strategy for immune reset in B-cell-mediated autoimmune diseases and warrants further clinical investigation."

CAR T-Cell Therapy • IO biomarker • Preclinical • Inflammatory Arthritis